Cumberland Pharmaceuticals CPIX Stock
Cumberland Pharmaceuticals Price Chart
Cumberland Pharmaceuticals CPIX Financial and Trading Overview
Cumberland Pharmaceuticals stock price | 4.3 USD |
Previous Close | 1.7 USD |
Open | 1.77 USD |
Bid | 0 USD x 3000 |
Ask | 0 USD x 1200 |
Day's Range | 1.7 - 1.77 USD |
52 Week Range | 1.54 - 2.91 USD |
Volume | 12.71K USD |
Avg. Volume | 29.77K USD |
Market Cap | 24.85M USD |
Beta (5Y Monthly) | 0.339788 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.46 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
CPIX Valuation Measures
Enterprise Value | 28.65M USD |
Trailing P/E | N/A |
Forward P/E | 12.285714 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.6203723 |
Price/Book (mrq) | 0.6825397 |
Enterprise Value/Revenue | 0.715 |
Enterprise Value/EBITDA | -28.234 |
Trading Information
Cumberland Pharmaceuticals Stock Price History
Beta (5Y Monthly) | 0.339788 |
52-Week Change | -11.34% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2.91 USD |
52 Week Low | 1.54 USD |
50-Day Moving Average | 1.75 USD |
200-Day Moving Average | 2.2 USD |
CPIX Share Statistics
Avg. Volume (3 month) | 29.77K USD |
Avg. Daily Volume (10-Days) | 32.25K USD |
Shares Outstanding | 14.45M |
Float | 8.32M |
Short Ratio | 0.66 |
% Held by Insiders | 45.31% |
% Held by Institutions | 17.45% |
Shares Short | 37.17K |
Short % of Float | 0.44% |
Short % of Shares Outstanding | 0.26% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -9.96% |
Operating Margin (ttm) | -14.83% |
Gross Margin | 79.63% |
EBITDA Margin | -2.53% |
Management Effectiveness
Return on Assets (ttm) | -3.99% |
Return on Equity (ttm) | -10.60% |
Income Statement
Revenue (ttm) | 40.06M USD |
Revenue Per Share (ttm) | 2.77 USD |
Quarterly Revenue Growth (yoy) | -17.50% |
Gross Profit (ttm) | 32.89M USD |
EBITDA | -1014566 USD |
Net Income Avi to Common (ttm) | -3992804 USD |
Diluted EPS (ttm) | -0.27 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 16.39M USD |
Total Cash Per Share (mrq) | 1.13 USD |
Total Debt (mrq) | 20.78M USD |
Total Debt/Equity (mrq) | 57.64 USD |
Current Ratio (mrq) | 1.704 |
Book Value Per Share (mrq) | 2.52 |
Cash Flow Statement
Operating Cash Flow (ttm) | 7.19M USD |
Levered Free Cash Flow (ttm) | 1.39M USD |
Profile of Cumberland Pharmaceuticals
Country | United States |
State | TN |
City | Nashville |
Address | 1600 West End Avenue |
ZIP | 37203 |
Phone | (615) 255-0068 |
Website | https://www.cumberlandpharma.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 85 |
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Q&A For Cumberland Pharmaceuticals Stock
What is a current CPIX stock price?
Cumberland Pharmaceuticals CPIX stock price today per share is 4.3 USD.
How to purchase Cumberland Pharmaceuticals stock?
You can buy CPIX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cumberland Pharmaceuticals?
The stock symbol or ticker of Cumberland Pharmaceuticals is CPIX.
Which industry does the Cumberland Pharmaceuticals company belong to?
The Cumberland Pharmaceuticals industry is Drug Manufacturers-Specialty & Generic.
How many shares does Cumberland Pharmaceuticals have in circulation?
The max supply of Cumberland Pharmaceuticals shares is 13.97M.
What is Cumberland Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Cumberland Pharmaceuticals PE Ratio is now.
What was Cumberland Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Cumberland Pharmaceuticals EPS is -0.46 USD over the trailing 12 months.
Which sector does the Cumberland Pharmaceuticals company belong to?
The Cumberland Pharmaceuticals sector is Healthcare.
Cumberland Pharmaceuticals CPIX included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
NASDAQ Global Select Market Com NQGS | 8098.63 USD — |
-5.98
|
— — | 8089.65 USD — | 8265.47 USD — | — - | — — |
NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 20257.83 USD — |
-5.96
|
— — | 20236.33 USD — | 20672.41 USD — | — - | — — |
- {{ link.label }} {{link}}